PRTG — Portage Biotech Share Price
Last trade - 00:00- $12.90m
- $10.46m
- 44
- 35
- 78
- 52
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.23 | ||
| Price to Tang. Book | 9.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -5100.76% | ||
| Return on Equity | -194.84% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is engaged in advancing therapies to improve long-term treatment, response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. Its adenosine antagonist platform include PORT-9 and PORT-8. PORT-9 and PORT-8 are in the preclinical stage. Its PORT-8 is a dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to address solid tumors. Its PORT-9 is an A2B antagonist designed to treat colorectal and gastrointestinal cancers. Its iNKT Engager platform includes PORT- 3, which is in Phase I.
Directors
- Gregory Bailey CHM
- Ian Walters CEO
- Allan Shaw CFO (55)
- Kam Shah DRC (69)
- Declan Doogan IND (69)
- Steven Mintz IND (45)
- Last Annual
- March 31st, 2024
- Last Interim
- September 30th, 2024
- Incorporated
- January 1st, 1970
- Public Since
- October 28th, 2013
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,645,449
- Address
- Clarence Thomas Building, Road Town, TORTOLA, VG1110
- Web
- https://portagebiotech.com/
- Phone
- +1 4169291806
- Contact
- Andrew Hudders
- Auditors
- Marcum LLP
Latest News for PRTG
Upcoming Events for PRTG
Q3 2025 Portage Biotech Inc Earnings Release
Q4 2025 Portage Biotech Inc Earnings Release
Q1 2026 Portage Biotech Inc Earnings Release
Similar to PRTG
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 22:40 UTC, shares in Portage Biotech are trading at $7.84. This share price information is delayed by 15 minutes.
Shares in Portage Biotech last closed at $7.84 and the price had moved by +77.22% over the past 365 days. In terms of relative price strength the Portage Biotech share price has outperformed the S&P500 Index by +66.63% over the past year.
The overall consensus recommendation for Portage Biotech is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePortage Biotech does not currently pay a dividend.
Portage Biotech does not currently pay a dividend.
Portage Biotech does not currently pay a dividend.
To buy shares in Portage Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $7.84, shares in Portage Biotech had a market capitalisation of $12.90m.
Here are the trading details for Portage Biotech:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PRTG
Based on an overall assessment of its quality, value and momentum Portage Biotech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Portage Biotech is $7.00. That is 10.71% below the last closing price of $7.84.
Analysts covering Portage Biotech currently have a consensus Earnings Per Share (EPS) forecast of -$0.52 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Portage Biotech. Over the past six months, its share price has outperformed the S&P500 Index by +41.73%.
As of the last closing price of $7.84, shares in Portage Biotech were trading +62.36% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Portage Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Portage Biotech's management team is headed by:
- Gregory Bailey - CHM
- Ian Walters - CEO
- Allan Shaw - CFO
- Kam Shah - DRC
- Declan Doogan - IND
- Steven Mintz - IND